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Abstract
Background: Distant metastasis are common in Renal cell carcinoma (RCC) nearly one forth of
the patients have metastasis at presentation while another 50% develop metastasis during the
follow-up. A small percentage of these are solitary metastasis. We describe survival after surgical
excision or radiotherapy of solitary metastatic lesion from renal cell carcinoma
Patients and methods: Between 1988–2001, 43 patients with solitary metastasis to different
sites from renal cell carcinoma underwent either surgical excision or radiotherapy were analyzed.
The solitary nature of the lesions was confirmed by investigations. All patients have had radical
nephrectomy for the primary lesion. Survival analysis was carried out by Kaplan Meier Method.
Results: All solitary metastatic lesions were treated with intent of cure either by excision or
radiotherapy. Of these, 13 patients had solitary metastasis at the time of presentation in whom 3-
year overall median survival was 26 months. The survival of those who developed solitary
metastases during follow-up after nephrectomy for primary was 45 months. The patients with long
interval between diagnosis and development of metastasis, early stage and low grade of the primary
tumor had better prognosis.
Conclusion: Complete resection of either synchronous or metachronous solitary metastases
from renal cell carcinoma is justified and can contribute to a long-term survival in this select group
of patients.
Background
Nearly 20–25% of patients with renal cell carcinoma
(RCC) have distant metastasis at presentation. Another
50% develop metastasis or local recurrence during follow-
up after the treatment of the primary [1]. RCC can recur at
any time after nephrectomy and usually metastasizes via
venous and lymphatic routes. Frequent sites of metastasis
include the lung parenchyma (50% to 60%), [2] bone
(30% to 40%), [3] liver (30% to 40%), and brain (5%)
[4]. Other rare sites of metastasis include pancreas [5,6],
Published: 20 July 2005
World Journal of Surgical Oncology 2005, 3:48 doi:10.1186/1477-7819-3-
48
Received: 20 December 2004
Accepted: 20 July 2005
This article is available from: http://www.wjso.com/content/3/1/48
© 2005 Thyavihally et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2005, 3:48 http://www.wjso.com/content/3/1/48
Page 2 of 9
(page number not for citation purposes)
adrenal gland [7,8], parotid gland [9], maxilla, pharynx
etc. Even with early-stage disease, late metastases can
occur after complete resection. However, after the devel-
opment of metastasis the prognosis is often poor, as non-
operative modalities for advanced renal carcinoma have
failed to improve survival significantly. The average sur-
vival of metastatic RCC is about 4 months and only 10%
of these survive for one year. Chemotherapy, hormonal
therapy, and radiotherapy have generally proved ineffec-
tive for primary lesion or metastatic deposits, but an
improved survival is seen with the use of immunotherapy
with either interleukins or interferon [10,11]. There is a
small subset of patients where solitary metastasis is
present either at the time of presentation or develops dur-
ing follow-up after nephrectomy these patients have a bet-
ter survival. An autopsy series showed that 8 to 11% of the
patients with metachronous metastases have a solitary
lesion [12]. With the introduction of immunotherapy or
immunochemotherapy for advanced renal cell carcinoma,
survival has improved for a subset of patients. Surgical
resection of the renal tumor and solitary metastases if
present is still the treatment of choice for these lesions
[13]. By modern perioperative management, even
extended resections of metastatic lesions can be per-
formed with limited morbidity and mortality [14]. The
present study reports the result of retrospective analysis of
the records of 43 patients treated for solitary synchronous
or metachronous metastases from renal cell carcinoma.
Patients and methods
Between 1988 and 2001, 1863 patients of RCC were
treated of these 43 cases had solitary metastasis to differ-
ent sites. Thirteen patients had synchronous solitary
metastsis, whereas 30 patients developed solitary metasta-
sis during follow-up after the treatment of the primary in
a metachronous fashion. The location and extent of the
metastatic disease was evaluated by various diagnostic
methods, which include chest radiograph, isotope bone
scan, liver function tests, and serum alkaline phophatase.
All patients underwent either ultrasound (USG) or com-
puterized tomography (CT) of abdomen to rule out local
recurrence. The patients with lymph node metastasis were
excluded from the analysis. An attempt was made to
obtain histological proof of the metastatic lesion either by
fine needle aspiration cytology (FNAC) or USG/CT guided
biopsy. The analysis was performed separately for patients
with synchronous and metachronous metastatic lesions.
Survival analysis was calculated by using Kaplan-Meier
test and survival was compared using Log-rank test.
Results
Synchronous group
Thirteen patients with synchronous solitary metastatic
disease included 10 males and 3 females. The age of the
patients ranged from 38 to 69 years with mean of 57 years.
The site of solitary metastases were bone in 6, lung in 3,
liver in 2, and 1 each in brain and opposite adrenal gland
(Table 1). All patients underwent radical nephrectomy for
the primary in the same sitting except in one patient with
brain metastasis, which was irradiated. One patient with
bone metastasis had positive surgical margin and received
radiotherapy. The median disease free survival was 25
months and the median overall survival was 26 months
with 3-year survival being 27% and none of the patients
surviving 5 years (Figure 1). Five patients who could
afford received interferon alpha treatment for relapse to
multiple sites. Due to small number of patients a sub-
group analysis was not carried out for these patients.
Metachronous group
Thirty patients developed metachronous solitary lesion
during follow-up after definitive treatment of the primary
renal cell carcinoma of the kidney. The age of the patients
ranged from 34 to 75 with the mean of 54 years. There
were 21 males and 9 female patients. The metastatic inter-
val varied between 3 to 33 months with mean of 16
months. The distribution of site of solitary metastasis was
bone in 13, lung in 6, liver in 3, brain in 2, and one each
in parotid, maxilla, pharyngeal wall, soft tissue shoulder,
opposite adrenal and gall bladder (Figure 2). Eleven
patients with bone metastases underwent excision of the
lesion and other 2 patients received definitive radiother-
apy. All patients with lung and liver metastases underwent
surgical excision. One patient with brain metastasis
received radiotherapy and other one had surgical excision
of the lesion. The patient with parotid lesion underwent
Table 1: Patient and tumor characteristics- synchronous solitary metastasis
Total No. of patients 13
Age 38–69 years (mean = 57)
Sex Male-10, Female-3
Site of metastasis Bone-6, Lung-3, Liver-2, Brain-1, Opposite adrenal-1
Pathological stage of primary pT1–3, pT2–6, pT3–4
Fuhrman's Grading Grade I-1, Grade II-4, Grade III-5, Grade IV-3World Journal of Surgical Oncology 2005, 3:48 http://www.wjso.com/content/3/1/48
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parotidectomy and the one with metastasis in soft tissue
shoulder had forequarter amputation. Adrenalectomy
and cholecystectomy was done for adrenal and gall blad-
der metastasis respectively. Primary tumor stage was
pT1in 9, pT2 in 13, and pT3 in 8 patients. The distribution
of histological types and the nuclear grading is shown in
the table 2.
Post metastatectomy overall median survival was 45
months. The 3-year survival rate was 60 % and 5-year sur-
vival was 38 % (Figure 3). The overall survival for those
patients in whom solitary metastasis occurred within one
year (n = 15) was 31 months compared to 63 months in
those who developed metastasis after one year (n = 15)
the difference was statistically significant (log rank test p =
0.03) (Figure 4). The three patients with liver metastasis
and 2 with brain metastasis behaved poorly with survival
of 6 to 20 months. Two patients with bone metastasis and
one patient with brain metastasis received radiotherapy
after excision due to positive surgical margins.
The overall post metastatectomy median survival was 63
months for pT1 tumor, 45 months for pT2 and 24 months
for pT3 tumors and the difference in the survival was sig-
nificant (log rank test p = 0.004) (Figure 5). There was also
significant difference in the survival (log rank test p =
0.001) among patients with Fuhrman's grade I to grade IV
disease (Figure 6). The patients with lung and bone metas-
tasis had overall mean survival of 62 months and those
with brain and liver metastasis was 22 months. Thirteen
patients received immunotherapy after relapse at multiple
Overall survival in patients with synchronous solitary metastasis Figure 1
Overall survival in patients with synchronous solitary metastasis.
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sites following treatment of the solitary metastasis. How-
ever, the number of patients in each group was small,
hence subgroup analysis could not be carried out for these
patients.
Discussion
RCC is known for its varied presentation and its propen-
sity to metastasize by way of both venous and lymphatic
routes. Ritchie and deKernion [15] found that 23% of
patients with RCC present initially with metastatic disease
and 25% develop metastatic disease within 5 years of
nephrectomy. RCC can, however, metastasize to virtually
any organ, including the thyroid, pancreas, skeletal mus-
cle, and skin or underlying soft tissue.
Despite the early promising results with immunotherapy,
a complete response occurs in less than 15% and is rarely
durable, emphasizing that metastatic disease best treated
with complete resection of the primary and metastatic
lesions where possible. Solitary metastases are identified
Ultrasonography showing solitary metachronous metastasis to gall bladder Figure 2
Ultrasonography showing solitary metachronous metastasis to gall bladder.
Table 2: Patient and tumor characteristics- metachronous solitary metastasis
Total No. of patients 30
Age 34–75 Years (Mean 54)
Sex Male-21, Female-9
Metastatic interval 3–33 months (Mean 16)
Site of metastasis Bone-13, Lung-6, Liver-3, Brain-2, Parotid-1, Maxilla-1, Pharyngeal wall-1, Gall bladder-1, Opposite 
adrenal-1, Soft tissue shoulder-1.
Histology of primary Conventional Clear cell carcinoma -25
Papillary-4
Chromophobe -1
Pathological stage of primary pT1–9, pT2–13, pT3–8
Fuhrman's Grading Grade I-5, Grade II-12, Grade III-7, Grade IV-6World Journal of Surgical Oncology 2005, 3:48 http://www.wjso.com/content/3/1/48
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at the time of diagnosis of renal cell carcinoma in 2% to
4% of patients. Depending on the location of the solitary
metastasis, radical nephrectomy [16] with excision of the
solitary metastatic lesion has been advocated, with 20% to
30% 5-year survival rates being reported.
Barney in 1961 [17] did nephrectomy and lobectomy for
lung metastasis and patient survived for 23 years. This
influenced many workers to perform excision of solitary
metastasis. Middleton [18] reviewed the literature and
concluded that the survival after surgical excision of soli-
tary metastatic lesions was 45% at 3-years and 34% at 5-
years. Tolia and Whitmore [19], Morrow et al [20], and
Jett et al [21] also reported similar 5-year survival after the
treatment of solitary metastatic tumors. Skinner et al [22]
reported a 29% 5-year survival in a series of 41 patients in
whom one or two metastases were excised surgically in
addition to nephrectomy. In our series, the 3 and 5-year
post metastatectomy survival was 58% and 35% respec-
tively in metachronous group of patients whereas 3-year
survival was 20% in the synchronous group, the higher
survival could be due to number of patients being loss to
follow-up and hence censored from the survival analysis.
Middleton [18] found significant difference in survival
between synchronous and metachronous solitary
metastases, synchronous group being the worst. O'Dea et
al [23] and Rafla [24] also agreed that the patients with
synchronous solitary metastasis have poor survival when
compared to patients who develop metastasis after
removal the primary tumor. Although the site of metasta-
sis was not significant in many reports we found patients
Overall survival of the patients with metachronous solitary metastasis Figure 3
Overall survival of the patients with metachronous solitary metastasis.
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with lung and bone metastases fared much better (median
62 months) than with liver and brain metastases (median
22 months). This could be due to the fact that not all
patients with brain metastasis had undergone surgical
resection, and more use of adjuvant treatment in patients
with lung or bone metastasis.
Most metachronous metastases are identified in the first
or second year after nephrectomy. Tally et al [25] Skinner
et al [22] and Tongaonkar et al [26] found that survival in
metachronous metastases which appeared before one year
after the nephrectomy was poor (median overall survival
33 months) when compared to one in whom metastases
appeared after one year (median overall survival 55
months). Our results also suggests that over all survival in
patients with disease free interval less than one year was
31 months when compared to 63 months in those disease
free intervals was more than one year.
We also noted significant difference in the survival among
patients of different primary tumor stage and Fuhrman's
nuclear grading with early stage and low grade having bet-
ter survival. Thus, the groups of patients who do better
with solitary metastasis excision are those with disease
free interval of more than one year, low primary tumor
stage, low grade and those with bone and pulmonary
Overall survival comparing patients with metachronous solitary metastasis occurring within 12 months versus those occurring  after 12 months Figure 4
Overall survival comparing patients with metachronous solitary metastasis occurring within 12 months versus those occurring 
after 12 months.
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parenchymal metastasis. However, the effect of treatment
modality and adjuvant immunotherapy can not be calcu-
lated due to smaller number of cases in the present series.
Conclusion
A small subset of patients with a solitary metastasis from
renal cell carcinoma and good general condition may
benefit from nephrectomy and resection/radiotherapy of
the metastatic lesion. Surgical excision can locally control
the tumor, and relieve pain. Patients with disease free
interval of more than one year before development of sol-
itary metastasis, early primary tumor stage, low-grade and
patients with bone and pulmonary parenchymal metasta-
sis appear to have better survival. We believe that the rel-
atively prolonged survival of these small cohort of
patients with solitary metastatic lesions from RCC justify
aggressive surgical excision involving multispecialty spe-
cialists with long-term survival, however, prospective
studies are needed before this can be recommended as
standard practice.
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